Microbix Reports Second Quarter Sales Up 149 Percent Over Last Year

Results Show Company On Track For Record Growth



Apr 19, 2001, 01:00 ET from Microbix Biosystems Inc.

    TORONTO, April 19 /PRNewswire/ - Microbix Biosystems Inc. (TSE:MBX) today
 reported sales for the second quarter ended March 31 were up 149% over the
 same period last year, and re-confirm the Company's aggressive sales forecasts
 for its product portfolio.
     "This quarter's growth resulted from increased demand for Microbix' range
 of molecular diagnostic products," said William J. Gastle, president and chief
 executive officer. "We expect sales momentum in these specialty biologicals to
 continue into the second half of our year."
     Added strength for the future is also expected from the Company's planned
 generic urokinase products, which are aimed at satisfying a large U.S. market.
 Management is in ongoing discussions and negotiations with a selected group of
 firms concerning both the financing and distribution of the product.
     Microbix specializes in developing and manufacturing tissue culture-
 derived biologicals for an emerging world market for biotherapeutic drugs and
 animal health products. In its specialty biologicals business, it makes
 reagents for building diagnostic products and tools used in biotechnology
 research.
     The Company has expertise in advanced culture, purification and process
 validation technologies. Its objective during the next decade is to become a
 major force in what is expected to be a $3 billion generic biotherapeutics
 market in North America.
     Emailed questions for management of current general interest to the
 company's "Virtual Conference" are posted with replies on its web site at:
 www.microbix.com. Send emails to: microbix@microbix.com
 
     This press release contains forward-looking statements which are subject
 to risks and uncertainties that could cause actual results to differ
 materially from those set forth in the forward-looking statements. These
 forward-looking statements represent the Company's judgment as of the date of
 this press release. The Company disclaims any intent or obligation to update
 these forward-looking statements.
 
 

SOURCE Microbix Biosystems Inc.
    TORONTO, April 19 /PRNewswire/ - Microbix Biosystems Inc. (TSE:MBX) today
 reported sales for the second quarter ended March 31 were up 149% over the
 same period last year, and re-confirm the Company's aggressive sales forecasts
 for its product portfolio.
     "This quarter's growth resulted from increased demand for Microbix' range
 of molecular diagnostic products," said William J. Gastle, president and chief
 executive officer. "We expect sales momentum in these specialty biologicals to
 continue into the second half of our year."
     Added strength for the future is also expected from the Company's planned
 generic urokinase products, which are aimed at satisfying a large U.S. market.
 Management is in ongoing discussions and negotiations with a selected group of
 firms concerning both the financing and distribution of the product.
     Microbix specializes in developing and manufacturing tissue culture-
 derived biologicals for an emerging world market for biotherapeutic drugs and
 animal health products. In its specialty biologicals business, it makes
 reagents for building diagnostic products and tools used in biotechnology
 research.
     The Company has expertise in advanced culture, purification and process
 validation technologies. Its objective during the next decade is to become a
 major force in what is expected to be a $3 billion generic biotherapeutics
 market in North America.
     Emailed questions for management of current general interest to the
 company's "Virtual Conference" are posted with replies on its web site at:
 www.microbix.com. Send emails to: microbix@microbix.com
 
     This press release contains forward-looking statements which are subject
 to risks and uncertainties that could cause actual results to differ
 materially from those set forth in the forward-looking statements. These
 forward-looking statements represent the Company's judgment as of the date of
 this press release. The Company disclaims any intent or obligation to update
 these forward-looking statements.
 
 SOURCE Microbix Biosystems Inc.